![[Aria Pharmaceuticals in Drug Discovery & Development] Aria Pharmaceuticals announces positive in vivo data for two idiopathic pulmonary fibrosis candidates](https://blog.ourcrowd.com/wp-content/uploads/2021/04/drug-discovery-and-development.jpg)
[Aria Pharmaceuticals in Drug Discovery & Development] Aria Pharmaceuticals announces positive in vivo data for two idiopathic pulmonary fibrosis candidates
Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) has announced that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated efficacy and tolerability in preclinical research. Read...
Read More![[Aria Pharmaceuticals in Life Science Leader] Andrew Radin orchestrates his AI discovery platform’s pivot to R&D with a harmonious name change and eyes on the clinic](https://blog.ourcrowd.com/wp-content/uploads/2021/09/endpoint-news-logo.jpg){kind=logo}
![[Aria Pharmaceuticals in Life Science Leader] My Journey From Skepticism To Conviction Regarding AI](https://blog.ourcrowd.com/wp-content/uploads/2021/09/life-science-leader.jpg)
